WS04.4 Guidance on the Use of Sputum Biomarkers to Monitor Treatment Response and Act As Trial Outcomes in Cystic Fibrosis

Methods: A cross-sectional experimental study was approved by Verona and Rovigo Ethic Committee.Clinical data, spirometry, N 2 multiple breath washout (MBW) and urine samples were collected from 29 CF pts (age 12.56 ± 4.08; 23 StCF, 6 ExCF) and 15 HC (age 13.36 ± 4.13).Urine VOCs analysis was performed with Cyranose320 ® .The output data were elaborated through multivariate analysis and Principal Component Analysis (PCA).Results: A number of Cyranose320 ® sensors (S5-7, S9, S12, S14, S17, S23) significantly distinguished between HC and CF pts; also, StCF could be discriminated from ExCf (S6, S7, S9, S11, S12, S14, S16, S17, S21, S23, S29).For sensors distinguishing HC from CF pts, AUC of ROC was more than accurate for S14 (0.82), good for S9 (0.75) and S17 (0.73).PCA identified PC2, which proved the best PC in predicting between HC and CF subsets.Spirometry distinguished HC from ExCF, but not from St CF, while N 2 MBW distinguished also StCF from HC. Conclusion:We here report the first use of E-nose on urine samples from CF pts to measure VOCs profiles: the latter could distinguish HC from CF pts, and among CF pts, StCF from ExCF.N 2 MBW distinguished all 3 populations, while spirometry only distinguished ExCF from HC.Further analyses and studies are needed to evaluate systemic VOCs role as a clinical outcome in CF.